INS and Insulin resistance: Meta-analysis of 13 prospective studies comprising 435 patients found that, independent of changes in IGF-I, fasting plasma glucose, fasting plasma insulin, HbA1c, and homeostatic model of assessment of insulin resistance (HOMA-I) all significantly improved with pegvisomant monotherapy, while only fasting plasma insulin improved in patients treated in combination with SRLs [82].